CSL Ltd - Product Pipeline Review

Global Markets Direct’s, ‘CSL Ltd - Product Pipeline Review - 2016’, provides an overview of the CSL Ltd’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by CSL Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of CSL Ltd

The report provides overview of CSL Ltd including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses CSL Ltd’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features CSL Ltd’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate CSL Ltd’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for CSL Ltd

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding CSL Ltd’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

CSL Ltd Snapshot 6

CSL Ltd Overview 6

Key Facts ...

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

CSL Ltd Snapshot 6

CSL Ltd Overview 6

Key Facts 6

CSL Ltd - Research and Development Overview 7

Key Therapeutic Areas 7

CSL Ltd - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Combination Treatment Modalities 12

Pipeline Products - Partnered Products 13

Partnered Products/Combination Treatment Modalities 14

Pipeline Products - Out-Licensed Products 15

Out-Licensed Products/Combination Treatment Modalities 16

CSL Ltd - Pipeline Products Glance 17

CSL Ltd - Late Stage Pipeline Products 17

Pre-Registration Products/Combination Treatment Modalities 17

Phase III Products/Combination Treatment Modalities 18

CSL Ltd - Clinical Stage Pipeline Products 19

Phase II Products/Combination Treatment Modalities 19

Phase I Products/Combination Treatment Modalities 20

CSL Ltd - Early Stage Pipeline Products 21

Preclinical Products/Combination Treatment Modalities 21

Discovery Products/Combination Treatment Modalities 22

CSL Ltd - Drug Profiles 23

(coagulation factor II (human) + coagulation factor VII (human) + coagulation factor IX (human) + coagulation factor X (human) + protein C (human) + protein S (human)) - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

Antibodies for Undisclosed Indication - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

antihemophilic factor (recombinant), single chain - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

C1 esterase inhibitor (human) - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

CSL-112 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

CSL-311 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

CSL-312 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

CSL-324 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

CSL-346 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

CSL-626 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

CSL-640 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

CSL-650 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

CSL-689 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

CSL-777 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

factor XIII (human) - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

fibrinogen (human) - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

haptoglobin + hemopexin - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

immune globulin (human) - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Monoclonal Antibodies for Undisclosed Indication - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

PODCRC-OHS - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Recombinant Protein for Bleeding and Clotting Disorders - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Recombinant Protein for Hemophilia - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

CSL Ltd - Pipeline Analysis 50

CSL Ltd - Pipeline Products by Target 50

CSL Ltd - Pipeline Products by Route of Administration 52

CSL Ltd - Pipeline Products by Molecule Type 53

CSL Ltd - Pipeline Products by Mechanism of Action 54

CSL Ltd - Dormant Projects 56

CSL Ltd - Company Statement 57

CSL Ltd - Locations And Subsidiaries 58

Head Office 58

Other Locations & Subsidiaries 58

Appendix 62

Methodology 62

Coverage 62

Secondary Research 62

Primary Research 62

Expert Panel Validation 62

Contact Us 62

Disclaimer 63

List of Tables

List of Tables

CSL Ltd, Key Facts 6

CSL Ltd - Pipeline by Indication, 2016 8

CSL Ltd - Pipeline by Stage of Development, 2016 ...

List of Tables

CSL Ltd, Key Facts 6

CSL Ltd - Pipeline by Indication, 2016 8

CSL Ltd - Pipeline by Stage of Development, 2016 10

CSL Ltd - Monotherapy Products in Pipeline, 2016 11

CSL Ltd - Combination Treatment Modalities in Pipeline, 2016 12

CSL Ltd - Partnered Products in Pipeline, 2016 13

CSL Ltd - Partnered Products/ Combination Treatment Modalities, 2016 14

CSL Ltd - Out-Licensed Products in Pipeline, 2016 15

CSL Ltd - Out-Licensed Products/ Combination Treatment Modalities, 2016 16

CSL Ltd - Pre-Registration, 2016 17

CSL Ltd - Phase III, 2016 18

CSL Ltd - Phase II, 2016 19

CSL Ltd - Phase I, 2016 20

CSL Ltd - Preclinical, 2016 21

CSL Ltd - Discovery, 2016 22

CSL Ltd - Pipeline by Target, 2016 51

CSL Ltd - Pipeline by Route of Administration, 2016 52

CSL Ltd - Pipeline by Molecule Type, 2016 53

CSL Ltd - Pipeline Products by Mechanism of Action, 2016 55

CSL Ltd - Dormant Developmental Projects,2016 56

CSL Ltd, Other Locations 58

CSL Ltd, Subsidiaries 59

List of Figures

List of Figures

CSL Ltd - Pipeline by Top 10 Indication, 2016 8

CSL Ltd - Pipeline by Stage of Development, 2016 10

CSL Ltd ...

List of Figures

CSL Ltd - Pipeline by Top 10 Indication, 2016 8

CSL Ltd - Pipeline by Stage of Development, 2016 10

CSL Ltd - Monotherapy Products in Pipeline, 2016 11

CSL Ltd - Combination Treatment Modalities in Pipeline, 2016 12

CSL Ltd - Out-Licensed Products in Pipeline, 2016 15

CSL Ltd - Pipeline by Top 10 Target, 2016 50

CSL Ltd - Pipeline by Route of Administration, 2016 52

CSL Ltd - Pipeline by Molecule Type, 2016 53

CSL Ltd - Pipeline Products by Top 10 Mechanism of Action, 2016 54

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports